106
Participants
Start Date
September 30, 2009
Primary Completion Date
November 30, 2012
Study Completion Date
April 30, 2014
bortezomib
Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
Feldkirch
Graz
Vienna
Brno
Vejle
Hamburg
Kiel
Mÿnchen
Athens
Huddinge
Stockholm
Adana
Ankara
Antalya
Eskişehir
Gebse
Istanbul
Izmir
Edinburgh
Sheffield Yorks
Wakefield
Lead Sponsor
Janssen-Cilag International NV
INDUSTRY